Sleep benefit in Parkinson's disease.
Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.
Merello
M
M
Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.
Hughes
A
A
Colosimo
C
C
Hoffman
M
M
Starkstein
S
S
Leiguarda
R
R
D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology*; D002940:Circadian Rhythm / Q000187:drug effects*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D011446:Prospective Studies; D012890:Sleep / Q000187:drug effects*; D011795:Surveys and Questionnaires; D013997:Time Factors
D000978:Antiparkinson Agents; D007980:Levodopa